Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2016; 37(02): 123
DOI: 10.4103/0971-5851.180147
LETTER TO EDITOR

Essential thrombocythemia: Busulphan revisited

Prasad R Koduri
Department of Medicine, The Division of Hematology-Oncology, Mediciti Hospital, Secretariat Road, Hyderabad - 500 063, Telangana, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
  PDF Download Permissions and Reprints


Publication History

Article published online:
12 July 2021

© 2016. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol 2015;90:162-73.
  • 2 Shvidel L, Sigler E, Haran M, Klepfish A, Duek A, Berrebi A, et al. Busulphan is safe and efficient treatment in elderly patients with essential thrombocythemia. Leukemia 2007;21:2071-2.
  • 3 Berrebi A, Shvidel L, Shtalrid M, Klepfish A. Short course of busulphan in essential thrombocythaemia: remodelling of an old strategy. Br J Haematol 2000;109:249-50.
  • 4 Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 2013;27:1874-81.
  • 5 Barbui T, Finazzi MC, Finazzi G. Front-line therapy in polycythemia vera and essential thrombocythemia. Blood Rev 2012;26:205-11.